A video explaining PTSD and cannabis as treatment.
Coming out Green!
Getting rid of the stigma of cannabis users will help making cannabis more accessible for everybody and reduce the fear some people have towards it.
People that use cannabis, either recreational or for medical reasons are as diverse as any other group and should not be treated any different than others.
Here are some people that are sharing their stories on Coming out Green!
There are longer interviews on their youtube channel.
CBD Crew seeds for medical grows in Canada.
CBD Crew have now obtained a license to export seeds to licensed medical growers in Canada.
If you have a medical grow and have any questions regarding our genetics or how to obtain seeds,
please contact us at [email protected]
The many faces of medical cannabis users!
Today cannabis users has many faces, maybe even you are one of them. The stereotype of the typical “stoner” being the only one using cannabis has been very misleading and social media has now given people the opportunity to see the diverse group of people utilizing cannabis for many different reasons.
Here is one group that has tremendously been helped by cannabis, children with epilepsy and seizure issues.
Read about some of them here: Faces of Cannabis
Clinical Trials of Cannabis finally to be done on humans.
This year will be an exiting year for cannabis research.
We are moving on form animal studies to human studies on certain illnesses, which is quite a big step in the right direction.
We are all of course very exited to see what these studies will show and hope they encourage mores studies on even more diseases.
.
Clinical Trials of Cannabis for Glioma (Spain)
This study will be done by Dr. Guillermo Velasco and Dr. Manuel Guzmán are two of the top cannabis researchers in the world. They have published numerous studies about how cannabinoids fight glioma, an aggressive form of brain cancer. For example, in 1998 they showed how tetrahydrocannabinol (THC) induces apoptosis in glioma cells. In 2011 they demonstrated THC even works with chemotherapy to kill brain cancer.
This study is actually sponsored by the cannabis movement itself. The Medical Cannabis Bike Tour, a European organization based in Amsterdam, have been biking long distances to raise awareness and collect sponsors to this great study. CBD Crew and many other companies have been proud sponsors of the project since it started. They have now collected 100,000€ for the trial to start in September this year. And they are now looking to raise another 180,000€ to keep founding the studies. If you or your company want to donate to this study, please contact Medical Cannabis Bike Tour.
Using Cannabis to Fight Multiple Myeloma
Multiple myeloma (MM) is an incurable cancer of immune plasma cells. While it can be held at bay with chemotherapy, it is virtually impossible to completely eliminate. The US-Israeli cannabis research firm One World Cannabis (OWC) is partnering with Tel Aviv’s Sheba Academic Medical Center to conduct preclinical studies of cannabis for MM. In addition to these basic science studies, OWC reports they have “received the Chaim Sheba Medical Center Helsinki Committee (Internal Review Board – IRB) approval to initiate human clinical studies in evaluation of cannabidiol (CBD) in combination with tetrahydrocannabinol (THC) as a novel multiple myeloma (cancer) treatment.”
There is scientific support for the effectiveness of cannabinoids against MM. One study showed CBD, either by itself or in synergy with a chemotherapeutic agent, inhibited proliferation and induced cell death in MM cells.
There are also rumors of a few more studies being conducted, but the information is not public yet.
We hope for as many studies as possible and we are very exited to see what results they will bring.
Source: #illegallyhealed
CBD Crew just joined Twitter ( yes, we know we are late… )
CBD Crew is now on Twitter as well. After experiencing people making profiles and posing as us we thought it be better if we actually had an account, so people could follow and share with the actual CBD Crew.
If you are a grower or user of our strains and tweet about it, do let us know!
We love to hear how you felt trying our strains and see those beautiful pictures of your grow.
CBD Crew grow rapports form Trichome World!
The great crew at Trichome World are doing a great job test growing all kinds of strains and making online rapports.
We are happy to see that the CBD Crew collection as been represented. Thanks for the good work Trichome World!
Read all their CBD Crew rapports here!
CBD Crew at Spannabis Barcelona 2015
CBD Crew had yet another great year at Spannabis, one of the biggest expos out there
regarding Cannabis culture!
We spoke to a lot of interesting people that shared their information and experiences
and also met a lot of new people seeking more knowledge.
Every year we notice that more and more people are coming to our stand with broader
knowledge about CBD/THC, so information is spreading fast.
So many people asked us about where to get THC/CBD rich cannabis oils for treatment
of friends and family, it’s sadly clear that the demand s big.
We hope to one day be able to help everybody that contacts us with cannabis oils for treatment,
but as of now we do not have the ability to do so due to the law.
We can only sell the seeds, the product people have to make themselves.
Which makes it even more important for people to start growing, making products
and store for the day somebody needs it. As cultivating takes time and time is often of the essence.
See our whole Facebook Album here : Spannabis 2015!
CBD-Rich Cannabis versus Single-Molecule CBD, by ProjectCBD.
There is a lot of confusion about the different CBD extracts out there and the effectiveness of extracting just a single molecule. Here is a release on the matter from ProjectCBD:
A groundbreaking study from Israel has documented the superior therapeutic properties of whole plant CBD-rich Cannabis extract as compared to synthetic, single-molecule cannabidiol (CBD).
Published in the journal Pharmacology & Pharmacy (Feb. 2015), the article directly challenges one of the sacred cows of Big Pharma and the medical-industrial complex — the notion that “crude” botanical preparations are inherently low grade and less effective than pure, single-molecule compounds.
Entitled “Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol,” the article is all the more noteworthy given the contribution of co-author Lumir Hanus, who was instrumental in the discovery of anandamide, the endogenous cannabinoid compound first identified in the mammalian brain in 1992.
Hanus and two Israeli colleagues from Hebrew University of Jerusalem surveyed the scientific literature and noted that during the past fifteen years numerous preclinical studies had focused on the anti-inflammatory effects of pure, single-molecule CBD in animal models of various pathologies, including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and diabetes. (See preclinical data regarding CBD.)
These studies showed that administration of pure, single-molecule CBD resulted in a bell-shaped dose-response curve, meaning that when the amount of CBD exceeded a certain point its therapeutic impact declined dramatically. “Healing was only observed when CBD was given within a very limited dose range, whereas no beneficial effect was achieved at either lower or higher doses,” the authors observed. This characteristic of single-molecule CBD—manifested as a bell-shaped dose response—imposes serious obstacles that limit its usefulness in a clinical context.
The Israeli team sought to determine whether the administration of a whole plant CBD-rich extract would also generate a bell-shaped dose-response curve when administered to mice. Or would cannabidiol extracted from CBD-rich Cannabis avoid this liability? “The aim of the present study,” the authors explained, “was to find a CBD source that could eliminate the bell-shaped dose-response of purified CBD.”
The scientists obtained a CBD-rich strain called “Avidekel” from Tikkun Olam, an Israeli medical marijuana producer. Referred to as “clone 202” in this study, Avidekel has hardly any THC and therefore is not intoxicating. The origins of Avidekel can be traced to Spain, where breeders developed several phenotypes of “Cannatonic” (as in “cannabis tonic”), including a strain that measures close to 20 percent CBD by dry weight with almost no intoxicating ingredients. (The same high-yielding CBD-dominant strain is known as “ACDC” in California.)
The Israeli researchers extracted CBD-rich oil from clone 202. The extract—consisting of 17.9 percent CBD, 1.1 percent THC, 1.1 percent cannabichromene (CBC), 0.2 percent cannabigerol (CBG), and “traces” of cannabinol (CBN) and cannabivarol (CBDV)—was given to mice to evaluate its anti-inflammatory and painkilling effect.
For comparative purposes, the scientists administered pure, synthetic CBD to another group of mice and assessed its anti-inflammatory and analgesic properties. They also compared the extent to which single-molecule CBD and whole plant CBD inhibited the production of tumor necrosis factor alpha (TNFa), a systemic inflammatory signaling molecule. Dysregulation of TNF-alpha production has been implicated in several diseases including cancer, Alzheimer’s, clinical depression, and irritable bowel syndrome.
The pure CBD tests confirmed the findings of earlier preclinical research. Once again, singe-molecule CBD administration generated a bell-shaped dose-response curve with a narrow therapeutic window.
Moreover, the Israeli researchers found that a small amount of CBD in the clone extract was needed for significant pain relief compared to the much larger amount of pure CBD required to achieve the same analgesic effect.
But a different dose response pattern was observed when the clone 202 extract was administered to mice. Rather than showing a bell-shaped curve, where a therapeutic effect could only be achieved at a certain concentration of pure CBD, the whole plant CBD-rich extract caused a direct, dose-dependent inhibition of pain, inflammation, and TNFa production. “In stark contrast to purified CBD,” the Israeli team reported, “the clone extract…provided a clear correlation between the anti-inflammatory and anti-nociceptive responses and the dose, with increasing responses upon increasing doses, which makes this plant medicine ideal for clinical uses.”
Moreover, the Israeli researchers found that a small amount of CBD in the clone extract was needed for significant pain relief compared to the much larger amount of pure CBD required to achieve the same analgesic effect. And whereas pure, single-molecule CBD precipitated a dramatic drop in efficacy if more than a specific dosage was administered, an “overdose” of whole plant CBD-rich extract did not undermine its therapeutic potency. When greater than an optimal dose of the clone 202 oil was administered, its effectiveness leveled off, suggesting that a medicinal plateau had been reached.
The Israeli study found that Cannabis clone 202 extract “is superior over CBD for the treatment of inflammatory conditions.” The greater efficiency of the whole plant extract might be explained by additive or synergistic interactions between CBD and dozens of minor phytocannabinoids and hundreds of non-cannabinoid plant compounds. “It is likely that other components in the extract synergize with CBD to achieve the desired anti-inflammatory action that may contribute to overcoming the bell-shaped dose-response of purified CBD,” the Israeli team surmised.
.” The greater efficiency of the whole plant extract might be explained by additive or synergistic interactions between CBD and dozens of minor phytocannabinoids and hundreds of non-cannabinoid plant compounds. “
The scientists also felt it was important to examine how the CBD-rich Cannabis extract compared with commercial painkillers and anti-inflammatory drugs. They found that both pure CBD and the clone 202 extract exhibited greater anti-inflammatory potency than aspirin. Aspirin, but not tramadol, registered a slight inhibitory effect on TNFa production, which was negligible in comparison to the strong inhibitory effect of pure CBD and clone 202.
The key finding that CBD in the presence of other Cannabis components improves the dose-response is supported by recent reports documenting the anti-proliferative effect of cannabidiol on tumor cells and the inhibitory effect of CBD on bladder contractility.
“A lot of research has been made to isolate and characterize isolated single constituents of traditional herbal medicine to find their rationale for therapeutic uses,” the Israeli team concluded. “However, our data together with those of others provide legitimation to introduce a new generation of phytopharmaceuticals to treat diseases that have hitherto been treated using synthetic drugs alone. The therapeutic synergy observed with plant extracts results in the requirement for a lower amount of active components, with consequent reduced adverse effects.”
Martin A. Lee is the director of Project CBD and the author of Smoke Signals: A Social History of Marijuana — Medical, Recreational, and Scientific.
8 Misconceptions About Cannabidiol (CBD),an important document that everybody who is passionate about medical cannabis should read.
We do get a lot of people asking us about CBD from Industrial hemp, can it be as fantastic as the advertisers sometimes promotes it?
Truth be told, very few studies has been done on the health benefits of industrial hemp oil. But the people at ProjectCBD would be some of the more educated people on this and this is what they say.
The “Good” Part of Pot: 8 Misconceptions
About Cannabidiol (CBD)
By Martin A. Lee / Project CBD
February 25, 2015
It doesn’t get you high, but it’s causing quite a buzz among medical scientists and patients. The past year has seen a surge of interest in cannabidiol (CBD), a non-intoxicating cannabis compound with significant therapeutic properties. Numerous commercial start-ups and internet retailers have jumped on the CBD bandwagon, touting CBD derived from industrial hemp as the next big thing, a miracle oil that can shrink tumors, quell seizures, and ease chronic pain—without making people feel “stoned.” But along with a growing awareness of cannabidiol as a potential health aide there has been a proliferation of misconceptions about CBD.
1. “CBD is medical. THC is recreational.” Project CBD receives many inquiries from around the world and oftentimes people say they are seeking “CBD, the medical part” of the plant, “not THC, the recreational part” that gets you high. Actually, THC, “The High Causer,” has awesome therapeutic properties. Scientists at the Scripps Research Center in San Diego reported that THC inhibits an enzyme implicated in the formation of beta-amyloid plaque, the hallmark of Alzheimer’s-related dementia. The federal government recognizes single-molecule THC as an anti-nausea compound and appetite booster, deeming it a Schedule III drug, a category reserved for medicinal substances with little abuse potential. But whole plant marijuana, the only natural source of THC, continues to be classified as a dangerous Schedule I drug with no medical value.
2. “THC is the bad cannabinoid. CBD is the good cannabinoid.” The drug warrior’s strategic retreat: Give ground on CBD while continuing to demonize THC. Diehard marijuana prohibitionists are exploiting the good news about CBD to further stigmatize high-THC cannabis, casting tetrahydrocannabinol as the bad cannabinoid, whereas CBD is framed as the good cannabinoid. Why? Because CBD doesn’t make you high like THC does. Project CBD categorically rejects this moralistic, reefer madness dichotomy in favor of whole plant cannabis therapeutics.
3. “CBD is most effective without THC.” THC and CBD are the power couple of cannabis compounds—they work best together. Scientific studies have established that CBD and THC interact synergistically to enhance each other’s therapeutic effects. British researchers have shown thatCBD potentiates THC’s anti-inflammatory properties in an animal model of colitis. Scientists at the California Pacific Medical Center in San Francisco determined that a combination of CBD and THC has a more potent anti-tumoral effect than either compound alone when tested on brain cancerand breast cancer cell lines. And extensive clinical research has demonstrated that CBD combined with THC is more beneficial for neuropathic pain than either compound as a single molecule.
4. “Single-molecule pharmaceuticals are superior to ‘crude’ whole plant medicinals.” According to the federal government, specific components of the marijuana plant (THC, CBD) have medical value, but the plant itself does not have medical value. Uncle Sam’s single-molecule blinders reflect a cultural and political bias that privileges Big Pharma products. Single-molecule medicine is the predominant corporate way, the FDA-approved way, but it’s not the only way, and it’s not necessarily the optimal way to benefit from cannabis therapeutics. Cannabis contains several hundred compounds, including various flavonoids, aromatic terpenes, and many minor cannabinoids in addition to THC and CBD. Each of these compounds has specific healing attributes, but when combined they create what scientists refer to as a holistic “entourage effect,” so that the therapeutic impact of the whole plant is greater than the sum of its single-molecule parts. The Food and Drug Administration, however, isn’t in the business of approving plants as medicine.
“CBD is CBD – It doesn’t matter where it comes from.”
Yes it does matter.
5. “Psychoactivity is inherently an adverse side effect.” According to politically correct drug war catechism, the marijuana high is an unwanted side effect. Big Pharma is keen on synthesizing medically active marijuana-like molecules that don’t make people high—although it’s not obvious why mild euphoric feelings are intrinsically negative for a sick person or a healthy person, for that matter. In ancient Greece, the word euphoria meant “having health,” a state of well-being. The euphoric qualities of cannabis, far from being an unwholesome side effect, are deeply implicated in the therapeutic value of the plant. “We should be thinking of cannabis as a medicine first,” said Dr. Tod Mikuriya, “that happens to have some psychoactive properties, as many medicines do, rather than as an intoxicant that happens to have a few therapeutic properties on the side.”
6. “CBD is legal in all 50 states.” Purveyors of imported, CBD-infused hemp oil claim it’s legal to market their wares anywhere in the United States as long as the oil contains less than 0.3 percent THC. Actually, it’s not so simple. Federal law prohibits U.S. farmers from growing hemp as a commercial crop, but the sale of imported, low-THC, industrial hemp products is permitted in the United States as long as these products are derived from the seed or stalk of the plant, not from the leaves and flowers. Here’s the catch: Cannabidiol can’t be pressed or extracted from hempseed. CBD can be extracted from the flower, leaves, and, only to a very minor extent, from the stalk of the hemp plant. Hemp oil start-ups lack credibility when they say their CBD comes from hempseed and stalk. Congress may soon vote to exempt industrial hemp and CBD from the definition of marijuana under the Controlled Substances Act. Such legislation would not be necessary if CBD derived from foreign-grown hemp was already legal throughout the United States.
7. “’CBD-only’ laws adequately serve the patient population.” Eleven U.S. state legislatures have passed “CBD only” (or, more accurately, “low THC”) laws, and other states are poised to follow suit. Some states restrict the sources of CBD-rich products and specify the diseases for which CBD can be accessed; others do not. Ostensibly these laws allow the use of CBD-infused oil derived from hemp or cannabis that measures less than 0.3 percent THC. But a CBD-rich remedy with little THC doesn’t work for everyone. Parents of epileptic children have found that adding some THC (or THCA, the raw unheated version of THC) helps with seizure control in many instances. For some epileptics, THC-dominant strains are more effective than CBD-rich products. The vast majority of patients are not well served by CBD-only laws. They need access to a broad spectrum of whole plant cannabis remedies, not just the low THC medicine. One size doesn’t fit all with respect to cannabis therapeutics, and neither does one compound or one product or one strain.
8. “CBD is CBD – It doesn’t matter where it comes from.” Yes it does matter. The flower-tops and leaves of some industrial hemp strains may be a viable source of CBD (legal issues notwithstanding), but hemp is by no means an optimal source of cannabidiol. Industrial hemp typically contains far less cannabidiol than CBD-rich cannabis. Huge amounts of industrial hemp are required to extract a small amount of CBD, thereby raising the risk of toxic contaminants because hemp is a “bio-accumulator” that draws heavy metals from the soil. Single-molecule CBD synthesized in a lab or extracted and refined from industrial hemp lacks critical medicinal terpenes and secondary cannabinoids found in cannabis strains. These compounds interact with CBD and THC to enhance their therapeutic benefits.
-Martin A Lee is the director of Project CBD and the author of Smoke Signals: A Social History of..
Many medical cannabis cannabis interest groups, like ParentsForPot, has also gone public warning people about the differences.
Here is their statement:
As respected members of the cannabis community, the undersigned groups and activists support full spectrum cannabis legislation and treatment for children with autism and seizure disorders. We agree that experience and research show proper and effective treatment requires the combination only the full cannabis plant can provide. We also agree that we need to support other organizations and activists who stand with us and concur that medical cannabis, by definition, includes the entire plant and all its chemical compounds.
As more parents learn that cannabis can help their children with autism and seizure disorders, it has become necessary to point out that the upshot of CBD only legislation and companies that produce CBD only products are giving what may be false hope to families who have exhausted other avenues of treatment.
We believe it is vital to understand the importance of using the entire cannabis plant as part of their solution. Parents who are worried that their children are “getting high” need to know that cannabis does not have the same psychoactive effect on the brain of a child with severe epilepsy or autism as it does on the average person. It actually works to slow the neurons that are firing so rapidly down, creating a healthier brain not a “high” brain. It is equally important for parents to know that they can give their children full plant cannabis without getting them “high.” Ingesting whole plant cold extract cannabis delivers non- psychoactive, non-psychotropic effects. This is an essential factor in building up the system that enables THC and CBD to work. It also allows the incorporation of the myriad beneficial components that cannabis provides.
The truth is that many parents who have tried CBD only treatments for their children with autism and epilepsy report no success or reduction in symptoms. They are forced to go to the black market to get the medicine they need. In fact, parents who are using straight THC as a rescue medication for their children’s seizures are seeing great results. Their children are cognitive and coherent instead of high and out of commission for a whole day.
Industrial hemp does not contain the amount of THC or CBD needed to make an effective treatment for epilepsy or autism. Also important to remember is that these CBD producers are unregulated; there is no proof that they are really providing what they promise. That, along with the lack of results are two good reasons to consider other options.
Parents, please feel free to contact the groups listed below to learn more about the differences between full plant and CBD only cannabis treatments to make a more informed decision. Your child’s life depends on it.
Websites:
www.parents4pot.org
www.uf4a.org
www.epsilonresearch.org
http://www.alternativeherbsls.net/
FB Groups:
Cannabis Oil Success Stories
CBD 4 Children With Epilepsy
Parents 4 Pot Education Group
National Cannabis Patients Wall
Treating Autism With Cannabis
Medical Cannabis: THCA and Alternatives for Success
Medical Cannabis: Whole Plant Therapies
Molecule Madness Education & Research Group
Resources:
http://www.collective-evolution.com/…/inform-yourself-abou…/
http://pediatriccannabistherapy.com/…/treatable-con…/autism/
http://www.ncbi.nlm.nih.gov/pubmed/23585028
http://emeraldwellnesscoop.com/…/introduction-to-the-endoc…/
http://www.autismdailynewscast.com/studies-finds-link-be…/…/
http://www.ncbi.nlm.nih.gov/pubmed/23653228
http://www.scribd.com/…/The-Endocannabinoid-System-as-it-Re…
http://theweek.com/…/speedreads-boy-with-autism-has-his-own…
http://www.medicaljane.com/…/cannabinoid-deficiency-may-ex…/#
http://www.inquisitr.com/…/marijuana-affects-autism-but-no…/
http://uf4a.org
https://cannacom.ca/index.php/cannabis-research
http://cannabisforautism.wordpress.com
http://www.autismdailynewscast.com/families-use-medical-…/…/
http://guardianlv.com/2014/…/medical-cannabis-treats-autism/
http://www.sciencedaily.com/releases/2012/…/121121145402.htm
http://www.letfreedomgrow.com/cmu/SamsStory.htm
http://www.huffingtonpost.com/tag/marijuana-autism/
http://www.truthonpot.com/2013/07/01/medical-ma…
http://www.hightimes.com/…/marijuana-may-be-used-treat-auti…
